Compare Medpace Holdings Inc (MEDP) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs NetEase Inc — how do they compare? Medpace Holdings Inc trades at $617.27 (market cap $16.82B), while NetEase Inc trades at $124.76 (market cap $76.09B). The key difference: NetEase Inc is far larger — about 4.5× Medpace Holdings Inc's market cap, and NetEase Inc pays a 2.45% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and NetEase Inc for 74 Days on average.
| MEDP | NTES | |
|---|---|---|
Market Cap | $16.82B | $76.09B |
Volume | 223,093 | 486,447 |
Sector | Health | Technology |
52-Week High | $630.19 | $152.85 |
52-Week Low | $393.42 | $109.26 |
Typical Hold Time | 14 Days | 74 Days |
Enterprise Value | $16.44B | $51.81B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
NetEase (NTES) trades at $120.61, up 1.29% with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show volatility with two misses in the last three quarters. Analyst consensus remains strongly bullish with 82% buy ratings and a $168 price target representing 39% upside potential.
The investment case balances strong profitability and cash generation against earnings volatility and competitive pressures. Key opportunities include consistent revenue growth and attractive valuation multiples, while risks center on gaming market competition and China regulatory environment. The stock presents value for long-term investors given the significant discount to analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
